Strand V, et al. - In patients with systemic lupus erythematosus (SLE) receiving belimumab, researchers reported long-term health-related quality of life (HRQoL) and fatigue results. In this continuation study, SLE patients who completed the Study of Belimumab in Subjects with SLE 76-week trial were enrolled. One hundred forty of the enrolled 268 patients completed the study. With belimumab plus standard therapy, long-term control of SLE disease activity translates into meaningful improvements in patient-reported fatigue and HRQoL.